while increasing TCA plasma concentration and adverse effects.belladonna alkaloidsbelladonna alkaloids and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.benztropinebenztropine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.bethanecholbethanechol increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.brimonidinedesipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.butabarbitalbutabarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.butalbitalbutalbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.carbacholcarbachol increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.carbamazepinecarbamazepine decreases levels of desipramine by increasing metabolism. Minor/Significance Unknown.cevimelinecevimeline increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.chlorpromazinedesipramine, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, chlorpromazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.chlorpropamidedesipramine increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.cisatracuriumcisatracurium and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.conjugated estrogensconjugated estrogens, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.conjugated estrogens, vaginalconjugated estrogens, vaginal, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.cyclizinecyclizine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.cyclobenzaprinecyclobenzaprine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.darifenacindarifenacin and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.desfluranedesflurane, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.dexmethylphenidatedexmethylphenidate increases effects of desipramine by decreasing metabolism. Minor/Significance Unknown.dicyclominedicyclomine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.diphenhydraminediphenhydramine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.desipramine and diphenhydramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.donepezildonepezil increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.echothiophate iodideechothiophate iodide increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.estradiolestradiol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens conjugated syntheticestrogens conjugated synthetic, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens esterifiedestrogens esterified, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.estropipateestropipate, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.ethanolethanol decreases levels of desipramine by increasing metabolism. Minor/Significance Unknown. Interaction esp. seen in detoxified alcoholics.ethinylestradiolethinylestradiol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.etomidateetomidate, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.eucalyptusdesipramine and eucalyptus both increase sedation. Minor/Significance Unknown.fesoterodinefesoterodine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.flavoxateflavoxate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.fluphenazinedesipramine, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.galantaminegalantamine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.glimepiridedesipramine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizidedesipramine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburidedesipramine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.glycopyrrolateglycopyrrolate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.glycopyrrolate inhaledglycopyrrolate inhaled and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.hydroxyprogesterone caproate (DSC)hydroxyprogesterone caproate (DSC), desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.insulin aspartdesipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirdesipramine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glarginedesipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisinedesipramine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisprodesipramine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHdesipramine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humandesipramine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.isoproterenolisoproterenol, desipramine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.ketamineketamine, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.lithiumlithium, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.mestranolmestranol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.metformindesipramine increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.miglitoldesipramine increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.nateglinidedesipramine increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.neostigmineneostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.onabotulinumtoxinAonabotulinumtoxinA and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.panax ginsengpanax ginseng increases effects of desipramine by pharmacodynamic synergism. Minor/Significance Unknown.pentobarbitalpentobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.perphenazinedesipramine, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.phenobarbitalphenobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.physostigminephysostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.pilocarpinepilocarpine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.pioglitazonedesipramine increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.pleurisy rootpleurisy root decreases effects of desipramine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.primidoneprimidone, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.prochlorperazinedesipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.progesterone micronizedprogesterone micronized, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.promazinedesipramine, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.promethazinedesipramine, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.propofolpropofol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.pyridostigminepyridostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.repaglinidedesipramine increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.rivastigminerivastigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.rosiglitazonedesipramine increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.sagedesipramine and sage both increase sedation. Minor/Significance Unknown.saxagliptindesipramine increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.secobarbitalsecobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.serdexmethylphenidate/dexmethylphenidateserdexmethylphenidate/dexmethylphenidate increases effects of desipramine by decreasing metabolism. Minor/Significance Unknown.sevofluranesevoflurane, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.sitagliptindesipramine increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.succinylcholinesuccinylcholine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.sulfamethoxazolesulfamethoxazole decreases levels of desipramine by unspecified interaction mechanism. Minor/Significance Unknown.thioridazinedesipramine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.tolazamidedesipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.tolbutamidedesipramine increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.trifluoperazinedesipramine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.vasopressindesipramine increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.verapamilverapamil increases levels of desipramine by decreasing metabolism. Minor/Significance Unknown.vildagliptindesipramine increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.zolpidemzolpidem, desipramine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.5-HTPMonitor Closely (1)desipramine and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.abirateroneMonitor Closely (1)abiraterone increases levels of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of desipramine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .acarboseMinor (1)desipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.aclidiniumMonitor Closely (1)aclidinium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.acrivastineMonitor Closely (1)acrivastine and desipramine both increase sedation. Use Caution/Monitor.adagrasibSerious - Use Alternative (1)adagrasib, desipramine. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.albuterolMonitor Closely (2)desipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. albuterol and desipramine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)desipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.alfentanilMonitor Closely (1)alfentanil and desipramine both increase sedation. Use Caution/Monitor.alfuzosinMonitor Closely (2)desipramine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and desipramine both increase QTc interval. Use Caution/Monitor.almotriptanMonitor Closely (1)almotriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.alprazolamMonitor Closely (1)alprazolam and desipramine both increase sedation. Use Caution/Monitor.amifampridineMonitor Closely (1)desipramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amiodaroneMonitor Closely (1)amiodarone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)desipramine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideMonitor Closely (2)desipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. amisulpride and desipramine both increase sedation. Use Caution/Monitor.amitriptylineMonitor Closely (2)amitriptyline and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. amitriptyline and desipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amitriptyline and desipramine both increase QTc interval. Avoid or Use Alternate Drug. amitriptyline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.amobarbitalMonitor Closely (1)amobarbital and desipramine both increase sedation. Use Caution/Monitor.Minor (1)amobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.amoxapineMonitor Closely (2)amoxapine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. amoxapine and desipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amoxapine and desipramine both increase QTc interval. Avoid or Use Alternate Drug. amoxapine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.anagrelideMonitor Closely (1)anagrelide and desipramine both increase QTc interval. Use Caution/Monitor.anticholinergic/sedative combosMinor (1)anticholinergic/sedative combos and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.apomorphineMonitor Closely (2)desipramine and apomorphine both increase sedation. Use Caution/Monitor. apomorphine and desipramine both increase QTc interval. Use Caution/Monitor.arformoterolMonitor Closely (2)desipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. arformoterol and desipramine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)desipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.aripiprazoleMonitor Closely (2)aripiprazole and desipramine both increase